You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

trudhesa Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Trudhesa, and what generic alternatives are available?

Trudhesa is a drug marketed by Impel Pharms and is included in one NDA. There are six patents protecting this drug.

This drug has sixty-four patent family members in sixteen countries.

The generic ingredient in TRUDHESA is dihydroergotamine mesylate. There are six drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the dihydroergotamine mesylate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Trudhesa

A generic version of trudhesa was approved as dihydroergotamine mesylate by PADAGIS US on April 28th, 2003.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for trudhesa?
  • What are the global sales for trudhesa?
  • What is Average Wholesale Price for trudhesa?
Summary for trudhesa
International Patents:64
US Patents:6
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 49
Patent Applications: 1,250
Drug Prices: Drug price information for trudhesa
What excipients (inactive ingredients) are in trudhesa?trudhesa excipients list
DailyMed Link:trudhesa at DailyMed
Drug patent expirations by year for trudhesa
Drug Prices for trudhesa

See drug prices for trudhesa

Pharmacology for trudhesa

US Patents and Regulatory Information for trudhesa

trudhesa is protected by six US patents and one FDA Regulatory Exclusivity.

Patents protecting trudhesa

Nasal drug delivery device
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nozzles for nasal drug delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Intranasal delivery of dihydroergotamine by precision olfactory device
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: NASAL ADMINISTRATION OF DIHYDROERGOTAMINE MESYLATE BY METERED SPRAY FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

In-line nasal delivery device
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nasal drug delivery device
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nozzles for nasal drug delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: NASAL ADMINISTRATION OF DIHYDROERGOTAMINE MESYLATE BY METERED SPRAY FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

FDA Regulatory Exclusivity protecting trudhesa

NEW PRODUCT
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Impel Pharms TRUDHESA dihydroergotamine mesylate SPRAY, METERED;NASAL 213436-001 Sep 2, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Impel Pharms TRUDHESA dihydroergotamine mesylate SPRAY, METERED;NASAL 213436-001 Sep 2, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Impel Pharms TRUDHESA dihydroergotamine mesylate SPRAY, METERED;NASAL 213436-001 Sep 2, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Impel Pharms TRUDHESA dihydroergotamine mesylate SPRAY, METERED;NASAL 213436-001 Sep 2, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Impel Pharms TRUDHESA dihydroergotamine mesylate SPRAY, METERED;NASAL 213436-001 Sep 2, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for trudhesa

See the table below for patents covering trudhesa around the world.

Country Patent Number Title Estimated Expiration
Canada 2828884 DISPOSITIF D'ADMINISTRATION DE MEDICAMENT PAR VOIE NASALE (NASAL DRUG DELIVERY DEVICE) ⤷  Sign Up
European Patent Office 3341059 DISPOSITIF D'ADMINISTRATION NASALE EN LIGNE (IN-LINE NASAL DELIVERY DEVICE) ⤷  Sign Up
South Africa 201801543 IN-LINE NASAL DELIVERY DEVICE ⤷  Sign Up
South Korea 20200118032 정밀 후각기관 장치에 의한 디하이드로에르고타민의 비강내 전달 ⤷  Sign Up
Australia 2022202900 Intranasal delivery of dihydroergotamine by precision olfactory device ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.